Arvinas Inc.

ARVN · United States

Share price · ARVN

$6.76-2.50 (-26.94%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ARVN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026-11.7%
  2. 3 Nov 2026-5.7%
  3. 13 Oct 2026-8.2%
  4. 5 Aug 2026-6.7%
  5. 4 Aug 2026+11.7%
  6. 12 Jun 2026+6.9%
  7. 1 May 2026+6.2%
  8. 1 Apr 2026+6.9%
  9. 23 Mar 2026-5.7%
  10. 18 Mar 2026-9.3%

Share of unusual movement by asset

For each asset, the share of ARVN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vepdegestrant (Veppanu)
events and moves
6shown from 8 days
ARV-102
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—35%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—44%

Assets

(4 total)
4Total Assets
1Approved
0Phase 3 / Filed
3Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Vepdegestrant(Veppanu)
Approved
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
Androgen receptor · Androgen receptor (degrader)Small molecule
Metastatic Castration-Resistant Prostate Cancer
Phase 1/2
KRAS G12DSmall molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Phase 1
LRRK2Small molecule
Parkinson's Disease

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
LuxdegalutamidePhase 2Metastatic Hormone-sensitive Prostate Cancer
Est. primary completion 2026-12-03 · NCT06991556 · CT.gov ↗
What to watch
Vepdegestrant · VeppanuPhase 3Breast Cancer
Est. primary completion 2026-12-30 · NCT05909397 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Vepdegestrant · VeppanuPhase 1/2Breast Cancer
Est. primary completion 2027-03-24 · NCT05548127 · CT.gov ↗
What to watch
May 2027 (1)
LuxdegalutamidePhase 1/2Prostate Cancer Metastatic
Est. primary completion 2027-05-25 · NCT05067140 · CT.gov ↗
What to watch
July 2027 (1)
LuxdegalutamidePhase 2Prostatic Cancer, Castration-Resistant
Est. primary completion 2027-07-16 · NCT07047118 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Vepdegestrant · VeppanuPhase 2Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer …
Est. primary completion 2029-08-27 · NCT04606446 · CT.gov ↗
What to watch
November 2029 (1)
LuxdegalutamidePhase 1/2Progressive Metastatic Castrate Resistant Prostate Cancer
Est. primary completion 2029-11-09 · NCT07206056 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 May 2026ApprovalVepdegestrantFDA approves VEPPANU (vepdegestrant)
US, FDA · Arvinas · Source ↗
8 August 2025Filing acceptedVepdegestrantFDA accepts vepdegestrant NDA
US, FDA · Arvinas · Source ↗
11 March 2025Topline resultVepdegestrantVERITAC-2 Phase 3 topline results
Arvinas · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.5M$47M$89M+ $470M short-term inv.$54M-$10M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$53M$94M+ $474M short-term inv.—-$48M operating cash flowreport ↗
2026-Q1—$60M$87M+ $528M short-term inv.$58M-$69M operating cash flowreport ↗
2025-Q3$42M$65M$102M+ $686M short-term inv.$35M-$59M operating cash flowreport ↗
2025-Q2$22M$69M$115M+ $746M short-term inv.$61M-$95M operating cash flowreport ↗
2025-Q1$189M$91M$81M+ $873M short-term inv.—-$89M operating cash flowreport ↗
2024-Q3$102M$87M$85M+ $1.0B short-term inv.$49M-$128M operating cash flowreport ↗
2024-Q2$77M$94M$160M+ $1.1B short-term inv.$35M$50M operating cash flowreport ↗
2024-Q1$25M$84M$94M+ $1.1B short-term inv.$69M-$98M operating cash flowreport ↗
2023-Q3$35M$86M$119M+ $885M short-term inv.$64M-$85M operating cash flowreport ↗
2023-Q2$55M$103M$96M+ $948M short-term inv.$67M-$89M operating cash flowreport ↗
2023-Q1$33M$95M$136M+ $993M short-term inv.$82M-$91M operating cash flowreport ↗
2022-Q3$30M$78M$138M+ $1.1B short-term inv.$66M-$67M operating cash flowreport ↗
2022-Q2$31M$75M$98M+ $1.3B short-term inv.$70M-$79M operating cash flowreport ↗
2022-Q1$24M$64M$67M+ $1.4B short-term inv.$63M-$57M operating cash flowreport ↗
2021-Q3$9.3M$41M$260M+ $1.3B short-term inv.$47M$682M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$263M$285M$143M+ $543M short-term inv.$20M-$274M operating cash flowreport ↗

For full-year 2025, Arvinas reported revenue of $262.6M, down 0.3% YoY, and R&D expenses of $285.2M, down 18.1% YoY. Cash and equivalents were $142.9M, with a net loss of -$80.8M for the year and a quarterly net burn of $80.8M.

Management guided that cash, cash equivalents, and marketable securities as of December 31, 2025 are sufficient to fund operations into the second half of 2028. Pipeline updates included oral presentation of ARV-102 Phase 1 data at AD/PD in March 2026, initial ARV-806 clinical data expected in 2026, continued ARV-393 dose escalation with a planned glofitamab combination cohort, initiation of a first-in-human Phase 1 trial for ARV-027, and ARV-6723 on track for Phase 1 initiation in mid-2026. The company also highlighted the vepdegestrant PDUFA action date of June 5, 2026, plans to select a commercialization partner for vepdegestrant, and the appointment of Randy Teel, Ph.D., as President and CEO.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$263M$348M$101M+ $939M short-term inv.$50M-$259M operating cash flowreport ↗
2023-FY$79M$380M$317M+ $949M short-term inv.$92M-$348M operating cash flowreport ↗
2022-FY$131M$315M$87M+ $1.1B short-term inv.$71M-$274M operating cash flowreport ↗
2021-FY$47M$180M$113M+ $1.4B short-term inv.$48M$559M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($268K), 23 sales ($1.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-09Loomis David K · VP, Chief Accounting OfficerOpen-market sale232$6.36$1KForm 4
2026-06-24Bain Linda · directorAward / grant15,527——Form 4
2026-06-24Cunningham Everett · directorAward / grant15,527——Form 4
2026-06-24Kennedy Edward Moore Jr. · directorAward / grant15,527——Form 4
2026-06-24Morrison Briggs · directorAward / grant15,527——Form 4
2026-06-24Norwalk Leslie V · directorAward / grant15,527——Form 4
2026-06-24Smaldone Alsup Laurie · directorAward / grant15,527——Form 4
2026-06-24Bain Linda · directorAward / grant (derivative)22,714——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 206 reporting institutions held 54.1M shares ($550.1M, 82.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.6,797,584$72.1M
2VANGUARD PORTFOLIO MANAGEMENT LLC3,889,628$41.2M
3D. E. Shaw & Co., Inc.3,638,567$38.6M
4Pfizer Inc3,457,815$34.9M
5VANGUARD CAPITAL MANAGEMENT LLC2,689,362$28.5M
6TCG Crossover Management, LLC2,387,461$25.3M
7ARMISTICE CAPITAL, LLC1,978,000$21.0M
8TWO SIGMA INVESTMENTS, LP1,832,114$19.4M
9STATE STREET CORP1,828,472$19.4M
10GEODE CAPITAL MANAGEMENT, LLC1,557,107$16.5M
11JACOBS LEVY EQUITY MANAGEMENT, INC1,441,521$15.3M
12Qube Research & Technologies Ltd1,201,635$12.7M
13CITADEL ADVISORS LLC1,180,988$12.5M
14FEDERATED HERMES, INC.1,140,715$12.1M
15Vestal Point Capital, LP905,465$9.6M